TuHURA Biosciences, Inc./NV — Director's Dealing 2017

Jul 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DelMar Pharmaceuticals, Inc. (DMPI)
CIK: 0001498382
Period of Report: 2017-07-07

Reporting Person: Zarrabian Saiid (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-07	Options (Right to Buy)	$2.11	A	36000	Acquired	2027-07-07	Common Stock (36000)	Direct
2017-07-07	Performance Stock Units	$	A	200000	Acquired	2022-07-07	Common Stock (200000)	Direct

Footnotes

F1: 12,000 options vest on June 30, 2018, and 3,000 options vest each three months thereafter starting September 30, 2018.

F2: Subject to stockholder approval of the Company's 2017 Omnibus Equity Incentive Plan at the Company's annual meeting, each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on targets related to the Company's financial performance.